Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)
PHASE3Active, not recruitingINTERVENTIONAL
Enrollment
861
Participants
Timeline
Start Date
September 16, 2016
Primary Completion Date
October 18, 2018
Study Completion Date
December 31, 2025
Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL
Pembrolizumab
Intravenous infusion
DRUG
Axitinib
Oral tablet
DRUG
Sunitinib
Oral capsule
All Listed Sponsors
lead
Merck Sharp & Dohme LLC
INDUSTRY
NCT02853331 - Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) | Biotech Hunter | Biotech Hunter